Recon: Celsius Snags $65M for Precision Medicines, Gilead to Build EU CART-T Facility

• Broad Institute Spinout Aims To Bring Precision Medicine To Autoimmune Disease (Forbes) (Fierce) (C&EN) (Endpoints)
• Roche pens death notice for NewLink IDO/TDO cancer collaboration (Fierce) (GEN)
• Insys sees no change in estimated litigation costs (Reuters) (Fierce)
• Indivior in settlement with Par Pharma over Suboxone (The Pharma Letter) (PBR)
• Waksal’s gene therapy spinoff MeiraGTx says it’s time to fly with an $86M IPO (Endpoints) (Fierce)
• Lilly's CGRP drug succeeds in 'worst kind of migraine' (BioPharma Dive) (Endpoints)
• TapImmune to merge with Baylor adoptive T-cell startup Marker (Fierce) (BioPharma Dive)

• Gilead finds new home in Europe for CAR-T manufacturing (BioPharma Dive) (Fierce) (The Pharma Letter) (Endpoints)
• Novartis CEO scrambles 5,000 managers for damage control as Swiss prosecutors and U.S. lawmakers circle (Fierce) (Bloomberg)
• Cambridge spinout CellCentric gets $26M for single-asset epigenetics approach to prostate cancer (Endpoints) (Business Weekly) (Scrip-$)
• Daiichi Sankyo Triples Down on Immuno-Oncology Collaboration with Zymeworks (GEN) (Fierce)
• Federal, provincial governments pen agreement to up Sask. health care money by $158M over 5 years (CBC News) (National Post)
• BioArctic, Uppsala University extend research collaboration on new antibody technology (Pharmabiz) (The Pharma Letter)
• Elsevier/Bayer study findings could cut animal testing (PharmaTimes) (pharmaphorum)
• FDA Commissioner Gottlieb: US could see lower drug prices if Europe pays more of its fair share (CNBC)
• As Ebola flares once again, a rapid global response invites cautious hope (STAT)
• AAM expresses concerns on USTR’s proposed China tariffs (The Pharma Letter)
• US medtech companies lobby against proposed Chinese tariffs (MassDevice)

• In the ‘diabetes belt,’ a small town grapples with growth of the world’s largest insulin maker (STAT)
• AbbVie and J&J reverse course on a price hike in face of criticism (STAT-$)
• Defending the ‘middlemen’ in the battle on drug prices (The Hill)
• Leading biotech investor Dr. Beth Seidenberg will step down from her role at Kleiner Perkins (Recode)
• The top 15 pharma companies by 2017 revenue (Fierce)
• Pfizer vet Travis Wager takes R&D reins at Aquinnah (Fierce) (Press)
• Azar threatens drugmakers with Trump's temper if they hike prices for no reason (Fierce)
• Novartis completes tender offer for all outstanding shares of AveXis (Pharmabiz) (Press)
• Trump's pharma plan highlights drug coupons (Axios)
• McKesson High Volume Solutions and Discount Drug Mart Partner to Build a Central Fill Pharmacy (Press)

• Azithromycin: A Generic Antibiotic That Continues To Provide Surprising Life-Saving Benefits (Forbes)
• Medicxi, RA Capital join $30M round for Dutch biotech’s late-stage transplantation med (Endpoints)
• Polyphor parlays a pathogen-specific antibiotic and I/O work into a $165M IPO for its PhIII program (Endpoints)
• Memory transferred between snails, challenging standard theory of how the brain remembers (STAT)
• Merck cements its novel drug approval dominance (EP Vantage)
• FDA Approves Subcutaneous Formulation Of Actemra (Genentech)
• Precise Control of Bulk, Multi-Component Nanostructures (Newswise)
• NIH funds three national cryo-EM service centers and training for new microscopists (NIH)
• Novartis ARROW trial to assess mechanistic superiority of direct IL-17A inhibition (Cosentyx) over IL-23 inhibition (Tremfya) (Press)
• Saama Technologies and ICON Commercialization and Outcomes Partner to Unlock the Value of Real World Evidence (RWE) (Press)
• Illumina Acquires Edico Genome to Accelerate Genomic Data Analysis (Press)

• The worries of medical equipment suppliers (Axios)
• PolarityTE aims to ‘wage war on skin grafts’ with regenerative tech (Drug Delivery Business News)
• Recreational ancestry DNA testing may reveal more than consumers bargained for (The Conversation)
• DHS warns of security flaws in GE, Philips, Silex medical devices (Healthcare IT News)
• St. Louis biotech firm receives FDA clearance for UTI detection device (St. Louis Business Journal-$) (Press)
• Caliber Imaging & Diagnostics, Inc. Announces FDA 510(k) Clearance for its VIVASCOPE System (Press)
• New Analysis Shows Medtronic Cardiac Resynchronization Therapy Feature Associated with Improved Patient Survival (Press)

• Amid Opioid Crisis, Chicago Drug Sales Rep License Gains National Momentum (Forbes)
• Democrats run on GOP health care 'sabotage' (Politico)
• As Trump railed against the ‘drug lobby,’ lawmakers funded by pharma watched from Rose Garden (STAT)
• Groups sue to stop Iowa's 'fetal heartbeat' abortion ban (Reuters)
• DoD responds to report calling Cerner EHR 'not operationally suitable' (Healthcare IT News)
• Apple Health Records: Where early adopters see the biggest impact so far (MobiHealthNews)
• Tom Price: Everyone should have health care coverage (CNN)
• Brand-Name Drug Cos. Not Liable For Generics' Tags In W.Va. (Law360-$)
• Trump Admin Poised To Give Rural Whites A Carve-Out On Medicaid Work Rules (TPM)
• 8,000 Volunteers in Week One of NIH Precision Medicine Study (Bloomberg-$)
• CMS renews Maryland's all-payer system (Modern Healthcare)
• Special Report: Philip Morris device knows a lot about your smoking habit (Reuters)
• Drug Discount Program: Status of Agency Efforts to Improve 340B Program Oversight (GAO)

• FDA Advisory Committee Calendar

• New mental health approach cuts hospital admissions 75 percent (PharmaTimes)
• Groups hails potential of organ on a chip tech for UK (PharmaTimes)
• NHS Confederation launches petition on NHS funding plan (PharmaTimes)

• Two surgeons in China developing a method to transplant a human head (CNBC)
• Kitov Pharma inks deal with China's Changshan Pharma (BioSpectrum)
• S. Windsor manufacturer announces Asia expansion (Hartford Business)
• Pharmacopoeial Discussion Group holds first videoconference meeting (PMDA)
• Promethera Biosciences Establishes Branch Office in Tokyo (Press)

• For Indian pharma, US FDA's CI checks account for 50% of regulatory audit (Pharmabiz)
• Discrimination kills 230,000 girls under five in India each year, study shows (The Guardian)
• Why IT and pharma mutual funds may be a good bet now (Economic Times)

• Apotex and Strides to merge their Australia businesses to become the country's largest generics player (Fierce)
• CStone Pharma begins phase I trial in Australia for anti-PD-1 antibody CS1003 to treat advanced solid tumors (Pharmabiz)
• Australia releases framework for My Health Record to deliver better outcomes for patients (OpenGov)
• All cancer patients should be prescribed exercise, Australian guidelines say (CBC News)
• Medicine labels: Guidance on TGO 91 and TGO 92 (TGA)
• Claims about hemp and CBD oils misleading consumers (TGA)

• How to solve Canada’s wait time problem (The Conversation)
• Cipher Pharmaceuticals Completes Acquisition of Canadian Business Portfolio of Cardiome Pharma (Press)
• Correvio Pharma Corp Completes Strategic Transaction with Cipher Pharmaceuticals (Press)

• Open CP on prescription-only medicines (ANVISA)
• Certificates will be sent electronically (ANVISA)

• Which Poor People Shouldn’t Have to Work for Aid? (NYT)
• In the midst of a massive opioid crisis, hospitals are experiencing an opioid shortage (Marketplace)
• More female leaders will help drive innovation in the medtech and biotech industries (STAT)
• Americans are paying more but getting less from health care (Axios)
• The Doctors Who Hate Insurance So Much They Go Without It (Bloomberg)
• Report finds cases of STDs reach all-time high in California (AP News)
• How to improve patient outcomes with digital health (pharmaphorum)